| My Account | Subscribe | Contact Us | Donate |
You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
If you are a physician, educator and medical professional who focus on the treatment of diabetes, then this is the must have resource for you.
Finally! A fresh take on the “professional” journal. Each bi-monthly issue cuts through the jargon and presents the most important information you need to enhance your practice and assist your patients.
Each bi-monthly issue of Diabetes Health Professional is a self-contained handbook covering products, educational resources and the latest diabetes research, complimented by balanced editorial focused on medical news, drug prescription information, clinical practice recommendations and changing treatment options.
Each quarter we send you the latest, most updated research guides, product guides and educational resource guides available for you and your patients.
Each week the Diabetes Health E-Newsletter delivers links to the very latest in news, reviews, blogs and videos from Diabetes Health direct to your inbox.
As a subscriber you'll get access to the amazing Diabetes Health Digital Advantage™ so you can read the current issue of Diabetes Health magazine online wherever you are!
You can cancel your newsletter subscription at anytime by clicking "Unsubscribe" on the bottom of any newsletter you receive
Then enter your new email address in the above form and click "Subscribe"
Latest Kidney Care (Nephropathy) Articles
How and when do we screen for microalbuminuria?
Annual screening for microalbuminuria (low levels of protein in the urine, indicating early signs of kidney disease) in type 1 diabetes should begin with puberty and/or after five-year disease duration of diabetes.
In patients with type 2, screening should begin at the time of diagnosis.
Consider an ACE Inhibitor
Numerous scientific studies have demonstrated that angiotensin converting enzyme (ACE) inhibitors, such as Vasotec, Altace, lisinopril and others, are the antihypertensive drugs of choice in all patients with diabetes. They reduce microalbuminuria, which is the hallmark of early diabetic kidney disease (nephropathy).
Therefore, the American Diabetes Association’s Standards of Care recommends these medications for all nonpregnant adult patients with diabetes.
Lifetime therapy with the drug is required.
Once begun, the dosage of the ACE inhibitor should be increased to the maximum tolerable dose for the greatest efficacy.
Possible reasons for the failure of ACE inhibitors to reduce microalbumin include:
Or Maybe an ARB
If ACE inhibitors cannot be tolerated, one of the angiotensin receptor blockers (ARBs), such as Cozaar and Diovan, should be substituted.
This group of drugs has also been demonstrated to reduce albuminuria and prevent kidney failure in both type 1 and type 2 diabetes. In certain cases, physicians may prescribe both classes of drugs for patients with diabetic nephropathy or hypertension.
Other anti-hypertensive agents may be useful, but none have yet been shown to be equivalent to the ACE inhibitors or the ARB drugs in preventing or reducing diabetic nephropathy.
What are the factors that contribute to diabetic kidney disease?
Non-modifiable risk factors (you can’t change these)
Modifiable risk factors (you can lower these risks)
Categories: Kidney Care (Nephropathy), Type 1 Issues, Type 2 Issues
Oct 1, 2004 -
Email to a Friend
Send a link to this page to your friends and colleagues.